OSCE stationDrNB Cardiology – Viva master list

ECG viva master list

127 ECGs and EP tracings · 330 viva questionsLast reviewed: October 2026
Merit MedScript seal

The ECGs and EP tracings examiners put in front of you most often. Parts A–C give the ECG hallmark, diagnosis, clinical risk and management, followed by five examiner cross-examination questions. Parts D–H cover the OSCE ECG and EP station — ischaemia, tachycardias, inherited syndromes, EP tracings and device strips — with the key feature, mechanism, clinical pearl and management, and distinction-level viva tips.

How to present in the viva: Name the rhythm and rate first, then the axis, intervals and the one hallmark you can point to on the trace. Give the diagnosis, the danger it carries and what you would do next.

ACore adult ECGs

1.Left bundle branch block (LBBB)

  • ECG hallmark: QRS ≥120 ms; broad, notched or slurred R waves in I, aVL, V5–V6; loss of septal q waves in lateral leads; deep QS/rS in V1; secondary discordant ST–T changes.
  • Diagnosis: Left bundle branch block
  • Clinical risk: Masks acute myocardial infarction; marker of LV dysfunction and dyssynchrony.
  • Management: Apply Sgarbossa / Smith-modified Sgarbossa criteria when ischaemia is suspected; echo for LV function.
Viva questions (5)
  • Q: New vs old LBBB — does it matter?A: Less than once thought. ESC 2023: any BBB with ongoing ischaemic symptoms is managed like STEMI (urgent angiography), whether the LBBB is known or new.
  • Q: What are the Sgarbossa criteria?A: Concordant ST elevation ≥1 mm in any lead (5 points), concordant ST depression ≥1 mm in V1–V3 (3 points), discordant ST elevation ≥5 mm (2 points); ≥3 points is highly specific for MI.
  • Q: What is the Smith modification?A: Replaces the 5 mm rule with a proportion: discordant ST elevation with ST/S ratio ≤ −0.25 — more sensitive.
  • Q: Can LBBB cause heart failure?A: Yes — electrical and mechanical dyssynchrony depress LV function (LBBB-induced cardiomyopathy).
  • Q: When is CRT Class I?A: Symptomatic HF, LVEF ≤35% despite GDMT, sinus rhythm, LBBB with QRS ≥150 ms (QRS 130–149 ms is Class IIa).

2.Right bundle branch block (RBBB)

  • ECG hallmark: QRS ≥120 ms; rSR′ (‘M’) in V1–V2; wide slurred S wave in I and V6.
  • Diagnosis: Right bundle branch block
  • Clinical risk: Usually benign; may signal RV volume or pressure overload (ASD, PE) or conduction disease.
  • Management: Echo if new or with symptoms/murmur; look for associated fascicular or AV block.
Viva questions (5)
  • Q: Is RBBB always pathological?A: No — common and often benign, but a new RBBB needs evaluation (ischaemia, PE, structural disease).
  • Q: Which congenital defect is classic?A: Secundum ASD — incomplete RBBB (rsR′ in V1) with right axis; look for the crochetage notch in inferior leads.
  • Q: Can RBBB hide a STEMI?A: Less than LBBB, because early septal activation is preserved, but ESC 2023 treats RBBB with ongoing ischaemic symptoms like a STEMI equivalent.
  • Q: RBBB with left axis deviation means?A: Bifascicular block (RBBB + LAFB).
  • Q: Does isolated RBBB need a pacemaker?A: No — only if it coexists with symptomatic or high-grade AV block.

3.Left anterior / posterior fascicular block

  • ECG hallmark: LAFB: axis −45° to −90°, qR in I and aVL, rS in II, III, aVF. LPFB: axis +90° to +180°, rS in I and aVL, qR in III and aVF (after excluding RVH, lateral MI and vertical heart).
  • Diagnosis: LAFB / LPFB
  • Clinical risk: Marker of conduction disease; may progress to bifascicular block.
  • Management: Compare with previous ECGs; evaluate for structural heart disease, especially with LPFB.
Viva questions (5)
  • Q: Which is more common?A: LAFB — the anterior fascicle is thin and has a single blood supply; LPFB is rare.
  • Q: Does isolated LAFB need pacing?A: No.
  • Q: What is LPFB usually associated with?A: Extensive disease — severe CAD or cardiomyopathy — because the posterior fascicle is broad with dual blood supply.
  • Q: How do you monitor progression?A: Serial ECGs; Holter if symptoms such as syncope.
  • Q: Does a fascicular block widen the QRS?A: Only minimally — QRS stays under 120 ms.

4.Bifascicular block

  • ECG hallmark: RBBB morphology in V1 with left axis deviation (qR in I/aVL) — or with right axis deviation for RBBB + LPFB.
  • Diagnosis: Bifascicular block (RBBB + LAFB, or RBBB + LPFB)
  • Clinical risk: Progression to high-grade AV block, especially if syncope.
  • Management: Holter or ILR; EPS if unexplained syncope.
Viva questions (5)
  • Q: Which fascicle remains?A: With RBBB + LAFB, only the left posterior fascicle conducts.
  • Q: Role of EPS?A: In unexplained syncope: HV interval ≥70 ms or infra-Hisian block on pacing indicates a pacemaker (ESC 2021).
  • Q: Risk of progression if asymptomatic?A: Low — about 1% per year; no prophylactic pacing.
  • Q: Is surgery safe?A: Yes; prophylactic temporary pacing is not routinely needed.
  • Q: Bifascicular block with syncope?A: EPS or ILR first; empirical pacing only in selected frail elderly patients.

5.Wolff–Parkinson–White (WPW) pattern

  • ECG hallmark: Short PR (<120 ms), delta wave, broad QRS with secondary ST–T changes.
  • Diagnosis: WPW syndrome (pre-excitation with tachycardia)
  • Clinical risk: Pre-excited AF conducting rapidly over the pathway can degenerate to VF.
  • Management: EPS and radiofrequency ablation (Class I for symptomatic pathways).
Viva questions (5)
  • Q: Why avoid AV-nodal blockers in pre-excited AF?A: Blocking the node favours conduction over the pathway and can precipitate VF.
  • Q: Most dangerous rhythm?A: Pre-excited AF with very rapid, irregular broad QRS complexes.
  • Q: Drug for haemodynamically stable pre-excited AF?A: Procainamide or ibutilide; synchronised DC cardioversion if unstable.
  • Q: Markers of a high-risk pathway?A: Shortest pre-excited RR in AF ≤250 ms, short pathway refractory period, multiple pathways.
  • Q: What is the delta wave?A: Early slurred ventricular activation through the accessory pathway, bypassing the AV node.

6.Atrial fibrillation

  • ECG hallmark: Irregularly irregular RR intervals, no P waves, fibrillatory baseline.
  • Diagnosis: Atrial fibrillation
  • Clinical risk: Stroke and systemic embolism; tachycardia-induced cardiomyopathy.
  • Management: Anticoagulation by CHA₂DS₂-VA (ESC 2024; CHA₂DS₂-VASc elsewhere); rate or rhythm control; treat risk factors.
Viva questions (5)
  • Q: What did ‘lone AF’ mean?A: AF without structural heart disease in younger patients — the term is now discouraged.
  • Q: Cardioversion without anticoagulation?A: Traditionally if AF <48 h; ESC 2024 advises early cardioversion only within 24 h unless anticoagulated for ≥3 weeks or TEE excludes thrombus.
  • Q: And after that window?A: ≥3 weeks of therapeutic anticoagulation or TEE first, then at least 4 weeks after cardioversion.
  • Q: Rate-control target?A: Lenient resting rate <110 bpm (RACE II), tighter if symptoms persist.
  • Q: Commonest trigger site?A: Pulmonary vein sleeves — the basis of pulmonary vein isolation.

7.Atrial flutter (typical)

  • ECG hallmark: Saw-tooth negative flutter waves in II, III, aVF at 250–350/min; positive flutter waves in V1; often 2:1 block (ventricular rate ~150).
  • Diagnosis: Typical atrial flutter
  • Clinical risk: 1:1 conduction (especially with class IC drugs) and stroke.
  • Management: Rate control and anticoagulation as for AF; CTI ablation is first-line for recurrent typical flutter.
Viva questions (5)
  • Q: What is typical flutter?A: Counter-clockwise macro-reentry around the tricuspid annulus, dependent on the cavotricuspid isthmus.
  • Q: Reverse typical?A: Clockwise CTI-dependent circuit — positive flutter waves inferiorly.
  • Q: Why is 2:1 block common?A: The AV node refractory period cannot conduct every flutter wave at ~300/min.
  • Q: Can it transition to AF?A: Yes — many patients later develop AF even after CTI ablation.
  • Q: Anticoagulation?A: Same thresholds as AF.

8.Complete heart block

  • ECG hallmark: Complete AV dissociation: regular P waves and regular, slower QRS complexes with no relationship.
  • Diagnosis: Third-degree AV block
  • Clinical risk: Syncope, asystole, sudden death.
  • Management: Transcutaneous or transvenous pacing if unstable; permanent pacemaker (Class I) once reversible causes are excluded.
Viva questions (5)
  • Q: Type of escape rhythm?A: Junctional (narrow QRS, 40–60/min) or ventricular (wide QRS, 20–40/min).
  • Q: Is atropine useful?A: Rarely — it may help nodal block but not infra-Hisian block.
  • Q: Causes in the young?A: Congenital (maternal anti-Ro), myocarditis, Lyme disease, sarcoidosis.
  • Q: When is asystole risk highest?A: Infra-Hisian block with a slow wide escape.
  • Q: Emergency treatment?A: Transcutaneous then transvenous pacing; isoprenaline or adrenaline as a bridge.

9.Mobitz type II AV block

  • ECG hallmark: Constant PR interval with sudden non-conducted P waves; often with bundle branch block.
  • Diagnosis: Second-degree AV block, Mobitz II
  • Clinical risk: Abrupt progression to complete heart block.
  • Management: Permanent pacemaker (Class I), even when asymptomatic.
Viva questions (5)
  • Q: Why is it dangerous?A: The block is usually infra-Hisian, with unreliable escape rhythms.
  • Q: Can you give beta-blockers?A: Avoid AV-nodal blocking drugs.
  • Q: How does it differ from Mobitz I?A: Mobitz I shows progressive PR prolongation before the dropped beat and is usually nodal.
  • Q: Site of block?A: His–Purkinje system.
  • Q: What about 2:1 block?A: Cannot be classified as I or II — look at QRS width, longer strips and response to exercise or atropine.

10.Anterior STEMI

  • ECG hallmark: ST elevation in V1–V4 (with I and aVL in proximal LAD occlusion).
  • Diagnosis: Anterior wall STEMI
  • Clinical risk: Large infarct, cardiogenic shock, LV thrombus.
  • Management: Primary PCI within 120 min of diagnosis (≤60 min if presenting to a PCI centre); fibrinolysis within 10 min of diagnosis if PCI is not achievable in time.
Viva questions (5)
  • Q: Culprit vessel?A: LAD.
  • Q: Mechanical complications?A: Apical VSD, LV aneurysm, LV thrombus, free-wall rupture.
  • Q: Reciprocal changes?A: ST depression in II, III, aVF — suggests a proximal LAD occlusion.
  • Q: If primary PCI is not possible within 120 min?A: Fibrinolysis, ideally within 10 min of diagnosis (ESC), then transfer for angiography within 2–24 h.
  • Q: Loading antiplatelets?A: Aspirin plus a P2Y12 inhibitor (prasugrel or ticagrelor for PCI; clopidogrel with fibrinolysis).

11.Inferior STEMI

  • ECG hallmark: ST elevation in II, III, aVF with reciprocal depression in I and aVL.
  • Diagnosis: Inferior wall STEMI
  • Clinical risk: RV infarction, AV block, hypotension.
  • Management: Record right-sided leads (V4R); primary PCI; avoid nitrates if RV involvement.
Viva questions (5)
  • Q: Culprit vessel?A: RCA in about 80% (ST elevation III > II), otherwise LCx.
  • Q: What is Kounis syndrome?A: Acute coronary syndrome triggered by an allergic or anaphylactic reaction.
  • Q: Why avoid nitrates in RV infarction?A: The RV is preload-dependent; venodilation causes profound hypotension.
  • Q: Where is the mirror image?A: ST depression in aVL (and I).
  • Q: Why bradycardia?A: Ischaemia of the AV nodal artery (from the RCA) and the Bezold–Jarisch reflex.

12.Posterior STEMI

  • ECG hallmark: Horizontal ST depression with upright T waves and tall R waves (R/S >1) in V1–V3; ST elevation ≥0.5 mm in V7–V9.
  • Diagnosis: Posterior wall MI
  • Clinical risk: Often missed; may be large.
  • Management: Record V7–V9; manage as STEMI with urgent reperfusion.
Viva questions (5)
  • Q: Why is it missed?A: No standard lead faces the posterior wall — changes appear as a mirror image in V1–V3.
  • Q: Culprit vessel?A: LCx or a dominant RCA.
  • Q: Which leads show the reciprocal change?A: V1–V3.
  • Q: Treatment?A: As STEMI — primary PCI.
  • Q: Prognosis if missed?A: Worse, because reperfusion is delayed.

13.Acute pericarditis

  • ECG hallmark: Diffuse concave ST elevation, PR depression (PR elevation in aVR), no reciprocal changes except aVR and V1.
  • Diagnosis: Acute pericarditis
  • Clinical risk: Effusion and tamponade; recurrence.
  • Management: NSAID or aspirin plus colchicine (Class I); exercise restriction.
Viva questions (5)
  • Q: How do you tell it from STEMI?A: Diffuse, concave ST elevation without reciprocal changes, plus PR depression.
  • Q: What is Spodick sign?A: Downsloping TP segment.
  • Q: When are steroids used?A: Second-line, at low dose, when NSAIDs are contraindicated or fail and infection is excluded.
  • Q: Signs of tamponade?A: Hypotension, raised JVP, pulsus paradoxus, electrical alternans.
  • Q: ECG evolution?A: Four stages: ST elevation → normalisation → T inversion → normal.

14.Hyperkalaemia

  • ECG hallmark: Peaked narrow-based T waves → PR prolongation and loss of P waves → QRS widening → sine wave.
  • Diagnosis: Severe hyperkalaemia
  • Clinical risk: Bradyarrhythmias, asystole, VF.
  • Management: IV calcium gluconate (membrane stabiliser) + insulin–dextrose ± salbutamol; remove potassium.
Viva questions (5)
  • Q: Earliest ECG sign?A: Tall, peaked T waves.
  • Q: What does calcium do?A: Stabilises the myocardial membrane — it does not lower potassium.
  • Q: How do you shift K⁺ into cells?A: Insulin with dextrose, nebulised salbutamol, bicarbonate if acidotic.
  • Q: How do you remove K⁺?A: Sodium zirconium cyclosilicate or patiromer, loop diuretics, dialysis.
  • Q: Can it mimic MI?A: Yes — pseudo-infarction and Brugada-like patterns.

15.Hypokalaemia

  • ECG hallmark: Prominent U waves, T-wave flattening, ST depression, apparent QT (QU) prolongation.
  • Diagnosis: Hypokalaemia
  • Clinical risk: Ventricular arrhythmias including torsades; digoxin toxicity.
  • Management: Replace potassium (and magnesium); avoid QT-prolonging drugs.
Viva questions (5)
  • Q: Why U waves?A: Delayed repolarisation, possibly of Purkinje or M cells.
  • Q: Typical arrhythmia?A: Torsades de pointes.
  • Q: Common cause?A: Diuretics.
  • Q: Target K⁺ in cardiac patients?A: ≥4.0 mmol/L.
  • Q: Interaction with digoxin?A: Hypokalaemia increases digoxin binding and toxicity.

16.Digoxin toxicity

  • ECG hallmark: Arrhythmias combining increased automaticity with AV block: atrial tachycardia with block, accelerated junctional rhythm, bidirectional VT, frequent ventricular ectopy. (The scooped ‘Salvador Dali’ ST is digoxin effect, not toxicity.)
  • Diagnosis: Digitalis toxicity
  • Clinical risk: Bidirectional VT, VF, high-grade AV block.
  • Management: Stop digoxin, correct K⁺ and Mg²⁺; digoxin-specific Fab fragments for life-threatening toxicity.
Viva questions (5)
  • Q: Mechanism?A: Na⁺/K⁺-ATPase inhibition → intracellular Ca²⁺ overload (delayed afterdepolarisations) plus vagal effects.
  • Q: What is bidirectional VT?A: Beat-to-beat alternating QRS axis — classic for digoxin toxicity and CPVT.
  • Q: Which electrolyte disturbance worsens it?A: Hypokalaemia (also hypomagnesaemia, hypercalcaemia).
  • Q: Does digoxin slow the heart?A: Yes — vagal effect on the sinus and AV nodes.
  • Q: Indications for Fab?A: Life-threatening arrhythmia, K⁺ >5–6 mmol/L, end-organ dysfunction, large ingestion.

17.Left ventricular hypertrophy

  • ECG hallmark: Sokolow–Lyon: S V1 + R V5 or V6 ≥35 mm; Cornell: R aVL + S V3 >28 mm (men) or >20 mm (women); ± strain pattern.
  • Diagnosis: Left ventricular hypertrophy
  • Clinical risk: Heart failure, AF, sudden death.
  • Management: Echo or CMR for wall thickness and cause; control blood pressure.
Viva questions (5)
  • Q: Cornell voltage criteria?A: R aVL + S V3 >28 mm in men, >20 mm in women.
  • Q: What is the strain pattern?A: Downsloping ST depression with asymmetric T inversion in leads with tall R waves.
  • Q: Common causes?A: Hypertension, aortic stenosis, HCM.
  • Q: Sensitivity of ECG criteria?A: Low (often <50%) but specificity is high.
  • Q: Does LVH regress?A: Yes — with BP control, especially ACEi/ARB.

18.Right ventricular hypertrophy

  • ECG hallmark: Right axis deviation; R/S >1 in V1 (R ≥7 mm); deep S in V5–V6; ± RV strain in V1–V3; right atrial enlargement.
  • Diagnosis: Right ventricular hypertrophy
  • Clinical risk: Pulmonary hypertension and RV failure.
  • Management: Echo for RV size and PASP; find the cause.
Viva questions (5)
  • Q: RV strain pattern?A: ST depression and T inversion in V1–V3.
  • Q: Causes?A: Pulmonary hypertension (COPD, mitral stenosis, PAH), pulmonary stenosis, ToF.
  • Q: Is a dominant R in V1 normal in children?A: Yes — in neonates and infants.
  • Q: What is the S1S2S3 pattern?A: S waves in I, II and III — seen in RVH (and as a normal variant).
  • Q: Bedside sign?A: Left parasternal heave.

19.Long QT syndrome

  • ECG hallmark: Prolonged QTc: ESC 2022 diagnosis QTc ≥480 ms, or ≥460 ms with unexplained syncope (or LQTS risk score >3).
  • Diagnosis: Long QT syndrome
  • Clinical risk: Torsades de pointes and sudden death.
  • Management: Beta-blocker (nadolol or propranolol); avoid QT-prolonging drugs; ICD after cardiac arrest.
Viva questions (5)
  • Q: Bazett formula?A: QTc = QT / √RR (seconds) — overcorrects at fast heart rates.
  • Q: First-line therapy?A: Non-selective beta-blocker (nadolol or propranolol).
  • Q: Triggers by genotype?A: LQT1 exercise/swimming; LQT2 emotion or sudden noise; LQT3 sleep or rest.
  • Q: Main genes?A: KCNQ1 (LQT1), KCNH2/hERG (LQT2), SCN5A (LQT3).
  • Q: Acquired causes?A: Drugs (antiarrhythmics, macrolides, antipsychotics), hypokalaemia, hypomagnesaemia, hypocalcaemia, bradycardia.

20.Brugada syndrome

  • ECG hallmark: Coved ST elevation ≥2 mm descending into a negative T wave in ≥1 of V1–V2 (standard or 2nd–3rd intercostal space).
  • Diagnosis: Brugada type 1 pattern
  • Clinical risk: Polymorphic VT/VF and sudden death, often at night or with fever.
  • Management: Treat fever, avoid trigger drugs (brugadadrugs.org); ICD after arrest (Class I) or arrhythmic syncope (Class IIa).
  • Brugada phenocopy: A Brugada-type pattern caused by ischaemia, fever, hyperkalaemia or mechanical compression resolves once the cause is treated, and a sodium-channel blocker challenge is negative.
  • Type 2 (saddle-back) pattern: Not diagnostic on its own; a sodium-channel blocker challenge (ajmaline, flecainide or procainamide) that unmasks a type 1 pattern confirms the diagnosis.
Viva questions (5)
  • Q: Triggers?A: Fever, vagal tone and sleep, large meals, sodium-channel blockers, cocaine, alcohol.
  • Q: Type 1 vs type 2?A: Coved (diagnostic) vs saddleback (non-diagnostic unless converted to type 1).
  • Q: How is it diagnosed?A: Spontaneous type 1, or drug-/fever-induced type 1 with supporting features (Shanghai score).
  • Q: Inheritance?A: Autosomal dominant; SCN5A in about 20–30%.
  • Q: Why ICD?A: It is the only proven protection against sudden death; quinidine or epicardial ablation for recurrent shocks.

BCongenital heart disease ECGs

21.Ostium secundum ASD

  • ECG hallmark: Incomplete or complete RBBB (rsR′ in V1) with right axis deviation; crochetage (notch) on R waves in inferior leads.
  • Diagnosis: Secundum atrial septal defect
  • Clinical risk: Atrial arrhythmias, pulmonary hypertension, paradoxical embolism.
  • Management: Echo (TTE/TEE) for size, rims and shunt; device or surgical closure.
Viva questions (5)
  • Q: Why the RBBB pattern?A: RV volume overload and RV outflow dilatation.
  • Q: Axis in secundum vs primum?A: Secundum: right or normal axis; primum: left (superior) axis.
  • Q: Does it cause AF?A: Yes — atrial flutter and AF increase with age.
  • Q: What is Lutembacher syndrome?A: ASD with mitral stenosis.
  • Q: When to close?A: Significant shunt with RV volume overload and PVR <3 WU (Qp:Qs ≥1.5 is the traditional cut-off).

22.Ostium primum ASD

  • ECG hallmark: RBBB pattern with left (superior) axis deviation and first-degree AV block.
  • Diagnosis: Primum ASD (partial AV septal defect)
  • Clinical risk: Mitral regurgitation through a cleft anterior leaflet; heart block.
  • Management: Echo for the mitral cleft; surgical repair (not device-closable).
Viva questions (5)
  • Q: Why left axis?A: Displacement of the conduction system in AV septal defects.
  • Q: Key ECG difference from secundum?A: Superior (left) axis and prolonged PR.
  • Q: Which valve is involved?A: Mitral (cleft anterior leaflet).
  • Q: Is it an endocardial cushion defect?A: Yes — a partial AV septal defect.
  • Q: Device closure?A: No — no inferior rim; surgical patch with cleft repair.

23.Tetralogy of Fallot

  • ECG hallmark: Right axis deviation, RVH with tall R in V1 and abrupt transition to rS in V2. After repair: RBBB.
  • Diagnosis: Tetralogy of Fallot
  • Clinical risk: Hypercyanotic spells (unrepaired); VT, sudden death and pulmonary regurgitation late after repair.
  • Management: Echo and CMR for RV volumes; pulmonary valve replacement when indicated.
Viva questions (5)
  • Q: Why RVH?A: RV pressure overload from RVOT obstruction with a large VSD.
  • Q: Late arrhythmia after repair?A: Scar-related VT around the ventriculotomy and VSD patch.
  • Q: Post-repair ECG?A: RBBB; QRS ≥180 ms predicts VT and sudden death.
  • Q: What is a tet spell?A: Hypercyanotic spell from increased right-to-left shunt (infundibular spasm, fall in SVR).
  • Q: Goal of surgery?A: Close the VSD and relieve RVOT obstruction.

24.Ebstein anomaly (with WPW)

  • ECG hallmark: Giant ‘Himalayan’ P waves; RBBB with low-amplitude, fractionated QRS; prolonged PR — or a short PR with delta wave (right-sided accessory pathway in 10–30%).
  • Diagnosis: Ebstein anomaly
  • Clinical risk: SVT, pre-excited AF and sudden death; RV failure.
  • Management: Echo or CMR; EPS and ablation of pathways (often multiple); surgical repair (cone).
Viva questions (5)
  • Q: Why giant P waves?A: Massive right atrial enlargement including the atrialised RV.
  • Q: Association with pre-excitation?A: WPW in about 10–30%, usually right-sided and often multiple pathways.
  • Q: Chest X-ray?A: Box-shaped (‘water-bottle’) heart with oligaemic lungs.
  • Q: Valve anatomy?A: Apical displacement of the septal tricuspid leaflet ≥8 mm/m² with an atrialised RV.
  • Q: Prognosis depends on?A: RV size and function, and arrhythmias.

25.d-TGA after arterial switch

  • ECG hallmark: Often near-normal; look for new Q waves or ST–T changes suggesting coronary ostial problems.
  • Diagnosis: Transposition after arterial switch (Jatene)
  • Clinical risk: Coronary ostial stenosis, neo-aortic root dilatation, supravalvar PA stenosis.
  • Management: Periodic imaging and ischaemia testing (stress imaging or CCTA).
Viva questions (5)
  • Q: What is the Jatene operation?A: Arterial switch with coronary button transfer.
  • Q: Main late risk?A: Coronary ostial stenosis or occlusion causing ischaemia.
  • Q: Can VT occur?A: Yes, though less often than after atrial switch.
  • Q: Why abnormal Q waves?A: Ischaemia or infarction from the transferred coronary buttons.
  • Q: What are Mustard and Senning?A: Atrial switch operations — they leave a systemic RV.

26.Congenitally corrected TGA (ccTGA)

  • ECG hallmark: Q waves in V1–V2 (and III, aVF) with absent q waves in V5–V6, from reversed septal activation; AV block.
  • Diagnosis: L-transposition (ccTGA)
  • Clinical risk: Progressive complete heart block (~2% per year); systemic RV failure; tricuspid regurgitation.
  • Management: Regular ECG/Holter; pacemaker when indicated (consider conduction-system or CRT pacing).
Viva questions (5)
  • Q: Why Q waves in V1?A: The septum depolarises right-to-left because the bundle branches are inverted.
  • Q: Why AV block?A: Anomalous, fragile AV node and long His bundle.
  • Q: Is the RV systemic?A: Yes — the morphological RV supports the systemic circulation.
  • Q: Does the systemic RV fail?A: Often by middle age, especially with tricuspid regurgitation.
  • Q: Surgical option?A: Double switch in selected young patients.

27.Severe pulmonary stenosis

  • ECG hallmark: Right axis deviation, RVH with qR or pure R in V1, RV strain, right atrial enlargement.
  • Diagnosis: Severe valvar pulmonary stenosis
  • Clinical risk: RV failure, exertional syncope.
  • Management: Balloon pulmonary valvuloplasty.
Viva questions (5)
  • Q: Intervention threshold?A: Peak Doppler gradient >64 mmHg (ESC 2020), or lower if symptomatic or RV dysfunction.
  • Q: Why qR in V1?A: Suprasystemic or systemic RV pressure.
  • Q: Noonan syndrome?A: Dysplastic pulmonary valve — responds less well to balloon valvuloplasty.
  • Q: Meaning of P pulmonale here?A: Right atrial enlargement from severe RV pressure overload.
  • Q: Treatment of choice?A: Balloon valvuloplasty for a domed valve.

28.Coarctation of the aorta

  • ECG hallmark: LVH by voltage with lateral strain in adults; RVH in infants.
  • Diagnosis: Coarctation of the aorta
  • Clinical risk: Hypertension, aortic dissection or rupture, intracranial aneurysm.
  • Management: Stenting or surgery; lifelong BP control and imaging.
Viva questions (5)
  • Q: Why LVH?A: Chronic pressure overload proximal to the coarctation.
  • Q: Most common association?A: Bicuspid aortic valve.
  • Q: Turner syndrome?A: Strong association.
  • Q: ECG feature in adults?A: LV strain in V5–V6.
  • Q: Bedside sign?A: Radio-femoral delay and arm–leg BP gradient.

30.Patent ductus arteriosus

  • ECG hallmark: LVH with deep narrow Q waves and tall R waves in I, aVL, V5–V6 (LV volume overload); LA enlargement.
  • Diagnosis: Patent ductus arteriosus
  • Clinical risk: Heart failure, endarteritis, pulmonary hypertension.
  • Management: Device or surgical closure.
Viva questions (5)
  • Q: Why deep Q waves?A: LV volume overload with septal hypertrophy.
  • Q: Murmur?A: Continuous ‘machinery’ murmur at the left infraclavicular area.
  • Q: Pulse?A: Bounding, with wide pulse pressure.
  • Q: Why does it persist in preterms?A: Immature ductal tissue with poor response to oxygen and high circulating PGE₂.
  • Q: Complication?A: Infective endarteritis.

31.Tricuspid atresia

  • ECG hallmark: Left axis deviation (superior), LVH, small RV forces, right atrial enlargement.
  • Diagnosis: Tricuspid atresia
  • Clinical risk: Cyanosis and heart failure.
  • Management: Staged single-ventricle palliation to Fontan.
Viva questions (5)
  • Q: Typical axis?A: Left (superior) — a classic clue among cyanotic lesions.
  • Q: Why LVH?A: The LV supports both circulations.
  • Q: Cyanotic?A: Yes.
  • Q: Surgical stages?A: Shunt or PA band → Glenn → Fontan.
  • Q: Obligatory pathway?A: An interatrial communication (ASD/PFO).

32.Hypoplastic left heart syndrome

  • ECG hallmark: Right axis deviation, RVH, right atrial enlargement, diminished left-sided forces (small R in V5–V6).
  • Diagnosis: HLHS
  • Clinical risk: Shock when the duct closes.
  • Management: Prostaglandin E₁ to keep the duct open; Norwood → Glenn → Fontan.
Viva questions (5)
  • Q: Duct-dependent?A: Yes — systemic flow depends on the PDA.
  • Q: Why small lateral forces?A: Tiny LV mass.
  • Q: Mortality?A: High without staged surgery or transplant.
  • Q: Stage 1?A: Norwood (or hybrid stenting and PA bands).
  • Q: Immediate drug?A: Prostaglandin E₁ infusion.

33.Obstructed TAPVR

  • ECG hallmark: Marked right axis deviation, RVH, right atrial enlargement.
  • Diagnosis: Obstructed total anomalous pulmonary venous return
  • Clinical risk: Severe pulmonary venous congestion, hypoxia and shock — a surgical emergency.
  • Management: Emergency surgical repair.
Viva questions (5)
  • Q: Why severe RVH?A: Pulmonary venous obstruction causes severe pulmonary hypertension.
  • Q: Chest X-ray?A: Small heart with a ground-glass pulmonary venous congestion pattern (the snowman is unobstructed supracardiac TAPVR).
  • Q: Cyanotic?A: Yes, severely.
  • Q: Urgency?A: Immediate surgery — prostaglandin can worsen pulmonary oedema.
  • Q: Commonest obstructed type?A: Infracardiac.

34.Unobstructed TAPVR

  • ECG hallmark: Right axis deviation, right atrial enlargement, RVH with rsR′ in V1.
  • Diagnosis: Unobstructed (supracardiac) TAPVR
  • Clinical risk: RV volume overload and later pulmonary hypertension.
  • Management: Elective surgical redirection of pulmonary veins to the LA.
Viva questions (5)
  • Q: Axis?A: Right.
  • Q: P wave?A: Tall P waves (right atrial enlargement).
  • Q: Cyanosis?A: Mild, because of complete mixing.
  • Q: What is the snowman sign?A: Dilated vertical vein, innominate vein and SVC above the heart.
  • Q: Can it cause PAH?A: Yes, if untreated.

35.Truncus arteriosus

  • ECG hallmark: Biventricular hypertrophy (Katz–Wachtel: large equiphasic QRS in mid-precordial leads).
  • Diagnosis: Truncus arteriosus
  • Clinical risk: Early heart failure and pulmonary vascular disease.
  • Management: Early surgical repair in infancy.
Viva questions (5)
  • Q: Why biventricular hypertrophy?A: Both ventricles eject into a single trunk at systemic pressure with high pulmonary flow.
  • Q: Cyanosis?A: Mild.
  • Q: Genetic association?A: 22q11 deletion (DiGeorge).
  • Q: Surgery?A: VSD closure and RV–PA conduit (Rastelli-type repair).
  • Q: Prognosis without repair?A: Poor — most die in infancy.

36.Fontan circulation

  • ECG hallmark: Sinus node dysfunction, junctional rhythm, intra-atrial re-entrant tachycardia (often slow flutter with 2:1 conduction); morphology depends on the ventricle.
  • Diagnosis: Single-ventricle (Fontan) patient
  • Clinical risk: Arrhythmias, thrombosis, failing Fontan, liver disease.
  • Management: Anticoagulation for atrial arrhythmia; ablation or Fontan conversion; transplant assessment if failing.
Viva questions (5)
  • Q: Commonest arrhythmia?A: Intra-atrial re-entrant tachycardia (IART).
  • Q: Why?A: Atrial dilatation and suture lines, especially after atriopulmonary Fontan.
  • Q: Drug?A: Amiodarone or dofetilide/sotalol with care; ablation preferred.
  • Q: Surgical arrhythmia option?A: Fontan conversion to TCPC with maze.
  • Q: Other complication?A: Protein-losing enteropathy, plastic bronchitis, FALD.

37.ASD after device closure

  • ECG hallmark: RBBB and right axis may regress; new atrial ectopy or AF early after implant.
  • Diagnosis: Post device closure ASD
  • Clinical risk: Device erosion, residual shunt, arrhythmia, thrombus.
  • Management: Echo at 1, 6 and 12 months; antiplatelet therapy for 6 months.
Viva questions (5)
  • Q: Why new arrhythmia?A: Device stretch and irritation of the atrial septum.
  • Q: What does erosion present with?A: Pericardial effusion or tamponade.
  • Q: How is residual shunt checked?A: TTE (with colour/bubble).
  • Q: Follow-up schedule?A: 1, 6 and 12 months, then periodically.
  • Q: Common device?A: Amplatzer septal occluder.

38.Acute myocarditis

  • ECG hallmark: Sinus tachycardia, diffuse ST–T changes or ST elevation, low QRS voltage, new AV block or BBB, ventricular ectopy.
  • Diagnosis: Acute myocarditis
  • Clinical risk: Fulminant heart failure, VT, heart block, sudden death.
  • Management: Supportive care and GDMT; inotropes or MCS if fulminant; biopsy-guided immunosuppression for giant-cell or eosinophilic myocarditis.
Viva questions (5)
  • Q: Why low QRS voltage?A: Myocardial oedema (and pericardial effusion).
  • Q: Arrhythmias?A: Ventricular ectopy, VT and AV block (think giant-cell myocarditis or sarcoid if AV block).
  • Q: What does it mimic?A: Acute MI — angiography may be needed.
  • Q: Key test?A: CMR (Lake Louise criteria); endomyocardial biopsy in fulminant or unexplained cases.
  • Q: Therapy?A: Supportive; temporary MCS bridge in fulminant cases; avoid NSAIDs and exercise for 3–6 months.

CHigh-yield ECGs for DrNB practicals

39.Wellens syndrome

  • ECG hallmark: Type A: biphasic T waves in V2–V3; Type B: deep symmetric T inversion in V2–V3; usually pain-free, minimal ST change, no Q waves.
  • Diagnosis: Wellens syndrome (critical proximal LAD stenosis)
  • Clinical risk: Impending extensive anterior MI.
  • Management: Urgent coronary angiography.
  • Critical action: Avoid stress testing — it can precipitate an extensive anterior MI; arrange early angiography.
Viva questions (5)
  • Q: Why is it dangerous?A: It marks a critical proximal LAD stenosis that has reperfused.
  • Q: Should you do a stress test?A: No — contraindicated.
  • Q: Is it a STEMI?A: No, but it is high-risk NSTE-ACS.
  • Q: Leads?A: V2–V3 (may extend V1–V6).
  • Q: Anatomy?A: Proximal LAD lesion.

40.De Winter T waves

  • ECG hallmark: 1–3 mm upsloping ST depression at the J point in V1–V6 with tall, symmetric T waves; often 0.5–1 mm ST elevation in aVR.
  • Diagnosis: De Winter pattern
  • Clinical risk: Acute proximal LAD occlusion.
  • Management: Treat as STEMI equivalent — immediate cath lab activation.
Viva questions (5)
  • Q: Why a STEMI equivalent?A: It represents acute LAD occlusion without classic ST elevation.
  • Q: ST shape?A: Upsloping ST depression with hyperacute T waves.
  • Q: Vessel?A: Proximal LAD.
  • Q: How common?A: About 2% of anterior MIs.
  • Q: Treatment?A: Primary PCI.

41.Mahaim (atriofascicular) pathway

  • ECG hallmark: Baseline ECG often normal or minimal pre-excitation; tachycardia is antidromic with LBBB morphology and left axis.
  • Diagnosis: Atriofascicular (Mahaim) pre-excitation
  • Clinical risk: Antidromic AV re-entrant tachycardia.
  • Management: EPS and ablation of the pathway on the lateral tricuspid annulus.
Viva questions (5)
  • Q: How does it differ from WPW?A: Slow, decremental, AV-node-like conduction — usually no delta wave at rest.
  • Q: Tachycardia type?A: Antidromic (pre-excited) tachycardia with LBBB morphology.
  • Q: Location?A: Right side — lateral tricuspid annulus to right bundle.
  • Q: PR interval?A: Usually normal.
  • Q: Treatment?A: Catheter ablation (target the Mahaim potential).

42.Arrhythmogenic right ventricular cardiomyopathy

  • ECG hallmark: Epsilon wave in V1–V3; T inversion in V1–V3 (age >14, no RBBB); terminal activation delay ≥55 ms; VT with LBBB morphology.
  • Diagnosis: ARVC
  • Clinical risk: VT and sudden death, especially with exercise.
  • Management: ICD by risk stratification (Class I after VT/VF); stop competitive and endurance sport; beta-blockers.
Viva questions (5)
  • Q: What is the epsilon wave?A: Low-amplitude notch after the QRS from delayed RV activation.
  • Q: T-wave inversion?A: V1–V3 or beyond in those over 14 without RBBB.
  • Q: Diagnostic criteria?A: 2010 Task Force criteria (Padua criteria for ACM).
  • Q: Genetics?A: Desmosomal genes, especially PKP2.
  • Q: VT morphology?A: LBBB, often with superior axis.

43.Benign early repolarisation

  • ECG hallmark: J-point elevation with notching or slurring; concave ST elevation, most in V2–V5; stable over time.
  • Diagnosis: Early repolarisation pattern
  • Clinical risk: Usually benign.
  • Management: Reassure if asymptomatic and features are benign.
  • BER vs pericarditis: Pericarditis: widespread concave ST elevation with PR depression (Spodick sign); ST/T ratio in V6 above 0.25. BER: J-point notching (fish-hook) mainly in V4–V6, stable over time.
Viva questions (5)
  • Q: How does it differ from pericarditis?A: No PR depression; ST/T ratio in V6 <0.25; stable over time.
  • Q: What is the high-risk variant?A: Inferolateral J waves with horizontal or descending ST (see later).
  • Q: Who has it?A: Young, athletic men.
  • Q: When to worry?A: Unexplained syncope or family history of sudden death.
  • Q: ST shape?A: Concave upward.

44.Osborn waves (hypothermia)

  • ECG hallmark: J (Osborn) waves — a positive hump at the J point, larger as temperature falls; bradycardia; shivering artefact.
  • Diagnosis: Hypothermia
  • Clinical risk: Bradycardia, AF, VF.
  • Management: Active rewarming; ECMO/ECLS for hypothermic arrest.
Viva questions (5)
  • Q: Temperature?A: Usually below 32°C.
  • Q: Mechanism of the J wave?A: Transmural gradient of the transient outward current (Ito).
  • Q: Arrhythmia?A: VF, especially below 28°C.
  • Q: Rewarming?A: Active external then internal; ECLS if cardiac arrest.
  • Q: Other causes of J waves?A: Hypercalcaemia, brain injury, subarachnoid haemorrhage.

45.Ashman phenomenon

  • ECG hallmark: Aberrant (usually RBBB-pattern) beat ending a short cycle that follows a long cycle, typically in AF.
  • Diagnosis: Ashman phenomenon
  • Clinical risk: Misdiagnosed as ventricular ectopy or VT.
  • Management: None specific — treat the underlying AF.
Viva questions (5)
  • Q: Why is the QRS wide?A: The refractory period lengthens after a long cycle, so an early beat meets a refractory right bundle.
  • Q: Usual rhythm?A: Atrial fibrillation.
  • Q: Why long–short?A: Refractoriness depends on the preceding cycle length.
  • Q: How do you distinguish it from VPCs?A: RBBB morphology, no compensatory pause, no fixed coupling.
  • Q: Significance?A: Benign.

46.Junctional escape rhythm

  • ECG hallmark: Narrow QRS at 40–60/min with absent or retrograde (inverted in II, III, aVF) P waves.
  • Diagnosis: Junctional escape rhythm
  • Clinical risk: Indicates sinus node failure or AV block.
  • Management: Find the cause (drugs, ischaemia, sinus node disease); pace if symptomatic.
Viva questions (5)
  • Q: Rate?A: 40–60/min.
  • Q: Why narrow QRS?A: The origin is above the bifurcation of the His bundle.
  • Q: P wave?A: Absent, or retrograde before or after the QRS.
  • Q: Causes?A: Beta-blockers, digoxin, calcium-channel blockers, ischaemia, sick sinus.
  • Q: Treatment?A: Treat the cause; pacemaker if symptomatic and irreversible.

47.Monomorphic ventricular tachycardia

  • ECG hallmark: Regular broad-complex tachycardia with AV dissociation, capture and fusion beats; concordance; extreme axis.
  • Diagnosis: Monomorphic VT
  • Clinical risk: Haemodynamic collapse and sudden death.
  • Management: Unstable: synchronised DC shock. Stable: cardioversion first-line (ESC 2022); procainamide or amiodarone if drugs used. ICD and ablation for secondary prevention.
  • Algorithms: Brugada or Vereckei (aVR) algorithms help separate VT from SVT with aberrancy; if in doubt, treat as VT.
Viva questions (5)
  • Q: Brugada criteria?A: Stepwise algorithm separating VT from SVT with aberrancy (absent RS, RS >100 ms, AV dissociation, morphology).
  • Q: Capture beat?A: A narrow sinus-conducted beat — proves AV dissociation.
  • Q: Haemodynamically stable VT?A: Synchronised cardioversion; procainamide (IIa) or amiodarone.
  • Q: Unstable?A: Immediate synchronised DC shock.
  • Q: Common substrate?A: Prior MI scar.

48.Torsades de pointes

  • ECG hallmark: Polymorphic VT with QRS axis twisting around the baseline, preceded by long QT and a short–long–short sequence.
  • Diagnosis: Torsades de pointes
  • Clinical risk: Syncope, VF.
  • Management: IV magnesium sulphate 2 g; stop QT-prolonging drugs; correct K⁺; overdrive pacing or isoprenaline for pause-dependent TdP.
  • If unstable: Sustained or pulseless torsades needs immediate unsynchronised defibrillation.
Viva questions (5)
  • Q: Preceding substrate?A: Long QT (congenital or acquired).
  • Q: First-line drug?A: IV magnesium.
  • Q: Pacing?A: Temporary overdrive pacing to shorten QT and prevent pauses.
  • Q: Causative drugs?A: Class IA and III antiarrhythmics, macrolides, antipsychotics, methadone.
  • Q: Electrolytes?A: Hypokalaemia, hypomagnesaemia.

49.Accelerated idioventricular rhythm

  • ECG hallmark: Regular wide-QRS rhythm at 40–100/min (faster than ventricular escape, slower than VT), often with fusion beats.
  • Diagnosis: AIVR
  • Clinical risk: Classic reperfusion rhythm after MI.
  • Management: Usually benign — observe.
Viva questions (5)
  • Q: Is it a reperfusion sign?A: Yes, commonly after thrombolysis or PCI.
  • Q: Haemodynamics?A: Usually stable.
  • Q: Suppress?A: Only if it causes haemodynamic compromise (loss of atrial kick).
  • Q: Rate?A: About 40–100/min.
  • Q: Why not treat with antiarrhythmics?A: It is self-limiting, and suppression may leave no escape rhythm.

50.‘Trifascicular’ block

  • ECG hallmark: RBBB + LAFB (or LPFB) + first-degree AV block. True trifascicular block is alternating bundle branch block.
  • Diagnosis: Bifascicular block with prolonged PR (‘trifascicular’)
  • Clinical risk: Progression to complete heart block, particularly with syncope.
  • Management: EPS if syncope; pacemaker for alternating BBB (Class I) or HV ≥70 ms.
Viva questions (5)
  • Q: Where is the PR delay?A: In the AV node or in the remaining fascicle (prolonged HV) — EPS tells which.
  • Q: Risk?A: Higher than bifascicular block alone if the delay is infra-Hisian.
  • Q: When EPS?A: Unexplained syncope.
  • Q: Who needs a pacemaker?A: Alternating BBB, HV ≥70 ms, or documented high-grade block.
  • Q: Difference from bifascicular block?A: Added PR prolongation.

51.LV strain pattern

  • ECG hallmark: Asymmetric downsloping ST depression with asymmetric T inversion in leads with tall R waves (I, aVL, V5–V6).
  • Diagnosis: LV strain (secondary repolarisation abnormality)
  • Clinical risk: Marker of LV hypertrophy and adverse prognosis.
  • Management: Echo for LVH; assess for hypertension, AS or HCM.
Viva questions (5)
  • Q: How does it differ from ischaemia?A: Strain is asymmetric and confined to tall-R leads; ischaemic T inversion is symmetric and territorial.
  • Q: Coronary vessel?A: None — reflects LVH and subendocardial supply–demand mismatch.
  • Q: Cause?A: LVH (hypertension, AS, HCM).
  • Q: Prognosis?A: Worse than LVH without strain.
  • Q: Echo?A: Shows LVH.

52.Right atrial enlargement (P pulmonale)

  • ECG hallmark: Tall peaked P ≥2.5 mm in II, III, aVF; prominent initial positive P in V1 ≥1.5 mm.
  • Diagnosis: P pulmonale
  • Clinical risk: Pulmonary hypertension, COPD, pulmonary or tricuspid stenosis.
  • Management: Echo for RA size and PASP.
Viva questions (5)
  • Q: Causes?A: COPD, pulmonary hypertension, pulmonary stenosis, tricuspid stenosis, congenital disease.
  • Q: Best lead?A: Lead II.
  • Q: Sensitivity?A: Poor.
  • Q: What is P mitrale?A: Broad, notched P (LA enlargement).
  • Q: Clinical correlate?A: Raised JVP with prominent a waves.

53.Left atrial enlargement (P mitrale)

  • ECG hallmark: Broad notched P ≥120 ms in II; terminal negative P in V1 ≥1 mm deep and ≥40 ms (Morris index).
  • Diagnosis: P mitrale
  • Clinical risk: AF; marker of mitral valve disease or LV diastolic dysfunction.
  • Management: Echo for LA size and mitral valve.
Viva questions (5)
  • Q: Pathophysiology?A: Delayed LA activation from LA enlargement.
  • Q: Classic disease?A: Mitral stenosis.
  • Q: Rhythm risk?A: AF.
  • Q: Lead V1 sign?A: Biphasic P with deep, broad terminal negative component.
  • Q: Chest X-ray sign?A: Double atrial contour and splayed carina.

54.Hypercalcaemia

  • ECG hallmark: Short QT from a short or absent ST segment; Osborn waves in severe cases.
  • Diagnosis: Hypercalcaemia
  • Clinical risk: Bradyarrhythmias, AV block, VF (rare).
  • Management: IV fluids, then bisphosphonates; treat the cause.
Viva questions (5)
  • Q: Why short QT?A: The ST segment shortens.
  • Q: Rhythm?A: Bradycardia and AV block.
  • Q: Common cause?A: Primary hyperparathyroidism and malignancy.
  • Q: Effect on repolarisation?A: Shortens phase 2 of the action potential.
  • Q: First-line treatment?A: IV saline rehydration.

55.Hypocalcaemia

  • ECG hallmark: Prolonged QT from ST-segment lengthening with a normal T wave.
  • Diagnosis: Hypocalcaemia
  • Clinical risk: Torsades (rare), laryngospasm, seizures, heart failure.
  • Management: IV calcium gluconate if symptomatic; correct magnesium.
Viva questions (5)
  • Q: Why long QT?A: The ST segment lengthens (prolonged phase 2).
  • Q: Arrhythmia?A: Torsades (uncommon).
  • Q: Chvostek sign?A: Facial twitch on tapping the facial nerve.
  • Q: First step if symptomatic?A: IV calcium gluconate.
  • Q: Why check magnesium?A: Hypomagnesaemia impairs PTH release and action, causing refractory hypocalcaemia.

56.Electrical alternans

  • ECG hallmark: Beat-to-beat alternation of QRS amplitude (total alternans of P, QRS and T is near-pathognomonic of tamponade), low voltage, sinus tachycardia.
  • Diagnosis: Electrical alternans (large effusion / tamponade)
  • Clinical risk: Cardiac tamponade.
  • Management: Urgent echo; pericardiocentesis if tamponade.
Viva questions (5)
  • Q: Mechanism?A: The heart swings within a large effusion.
  • Q: Is it always tamponade?A: No — it reflects a large effusion; tamponade is a clinical and echo diagnosis.
  • Q: Pulse?A: Pulsus paradoxus.
  • Q: First test?A: Echocardiography.
  • Q: Urgency?A: Pericardiocentesis is urgent if tamponade.

57.Sick sinus syndrome

  • ECG hallmark: Sinus bradycardia, pauses or SA exit block, alternating with paroxysmal AF/flutter or SVT.
  • Diagnosis: Sick sinus syndrome (tachy–brady)
  • Clinical risk: Syncope; stroke from AF.
  • Management: Pacemaker if symptoms correlate with bradycardia (Class I); anticoagulate AF.
Viva questions (5)
  • Q: Components?A: Bradycardia or pauses plus atrial tachyarrhythmias.
  • Q: Main symptom?A: Syncope or presyncope, often at termination of tachycardia.
  • Q: Pacemaker?A: Indicated when symptoms are linked to bradycardia.
  • Q: Why stroke?A: Episodes of AF.
  • Q: Typical age?A: Elderly.

58.Ventricular escape (idioventricular) rhythm

  • ECG hallmark: Wide QRS rhythm at 20–40/min without preceding P waves (or with AV dissociation).
  • Diagnosis: Ventricular escape rhythm
  • Clinical risk: Severe AV block or sinus arrest; asystole.
  • Management: Temporary (transcutaneous or transvenous) pacing, then permanent pacing.
Viva questions (5)
  • Q: Origin?A: Ventricular myocardium or distal Purkinje fibres.
  • Q: Why dangerous?A: Slow and unreliable — can stop.
  • Q: Rate?A: 20–40/min.
  • Q: How does it differ from junctional escape?A: Wide QRS and slower rate.
  • Q: Treatment?A: Pacing; treat the cause (e.g. hyperkalaemia, ischaemia).

59.Flecainide toxicity

  • ECG hallmark: Marked QRS widening, PR prolongation, Brugada-like changes, wide-complex tachycardia.
  • Diagnosis: Class IC drug toxicity
  • Clinical risk: Monomorphic VT, VF, cardiogenic shock.
  • Management: IV hypertonic sodium bicarbonate; consider lipid emulsion or ECMO in refractory shock.
Viva questions (5)
  • Q: Mechanism?A: Class IC sodium-channel block with slow unbinding kinetics.
  • Q: Why bicarbonate?A: Sodium load overcomes the block and alkalosis reduces drug binding.
  • Q: Arrhythmia?A: Wide monomorphic VT.
  • Q: Key ECG sign?A: Progressive QRS prolongation.
  • Q: Prognosis?A: High mortality if not treated quickly.

60.Hypertrophic cardiomyopathy

  • ECG hallmark: LVH voltage with deep narrow ‘dagger’ Q waves in I, aVL, V5–V6 (or inferior); giant negative T waves in apical HCM.
  • Diagnosis: Hypertrophic cardiomyopathy
  • Clinical risk: Sudden cardiac death; AF; heart failure.
  • Management: SCD risk stratification (HCM Risk-SCD / ACC-AHA factors); beta-blocker; myosin inhibitor (mavacamten) for obstructive HCM.
Viva questions (5)
  • Q: Why dagger Q waves?A: Septal hypertrophy exaggerates septal depolarisation forces.
  • Q: SCD risk factors?A: Unexplained syncope, family history of SCD, wall thickness ≥30 mm, NSVT, LGE ≥15%, apical aneurysm, LVEF <50%.
  • Q: First-line drug?A: Non-vasodilating beta-blocker.
  • Q: Cause of obstruction?A: Systolic anterior motion (SAM) of the mitral valve.
  • Q: Giant T inversion means?A: Apical HCM (Yamaguchi).

61.Acute pulmonary embolism

  • ECG hallmark: Sinus tachycardia (commonest); S1Q3T3; new RBBB; right axis; T inversion in V1–V4 and III.
  • Diagnosis: Acute pulmonary embolism
  • Clinical risk: Haemodynamic collapse from acute RV failure.
  • Management: Anticoagulation; systemic thrombolysis for high-risk PE.
Viva questions (5)
  • Q: Classic pattern?A: S1Q3T3 — specific but insensitive.
  • Q: Commonest ECG finding?A: Sinus tachycardia.
  • Q: Why right axis?A: Acute RV pressure overload.
  • Q: Where is T inversion?A: V1–V4 and III — marks RV strain and worse prognosis.
  • Q: High-risk features?A: Hypotension or shock.

62.Digoxin effect

  • ECG hallmark: Scooped (‘reverse tick’, Salvador Dali) ST depression in lateral leads, short QT, flattened T waves.
  • Diagnosis: Digoxin effect (therapeutic)
  • Clinical risk: None by itself — not a sign of toxicity.
  • Management: No change needed; check level and K⁺ if toxicity suspected.
Viva questions (5)
  • Q: How does it differ from toxicity?A: Toxicity produces arrhythmias or AV block.
  • Q: Mechanism?A: Shortened ventricular action potential and repolarisation.
  • Q: Is it ischaemia?A: No.
  • Q: Leads?A: Lateral (V4–V6) and inferior.
  • Q: Significance?A: Marker of digoxin use only.

63.High-risk early repolarisation

  • ECG hallmark: J-point elevation ≥1 mm in ≥2 inferior or lateral leads with horizontal or descending ST segment.
  • Diagnosis: Early repolarisation pattern — high risk
  • Clinical risk: VF and sudden death (early repolarisation syndrome).
  • Management: ICD after resuscitated arrest (Class I); may be considered (IIb) for arrhythmic syncope with high-risk features.
Viva questions (5)
  • Q: What makes it high risk?A: Inferolateral distribution, J ≥2 mm, and horizontal or descending ST.
  • Q: Population?A: Young men.
  • Q: When ICD?A: After resuscitated cardiac arrest.
  • Q: How to tell from MI?A: Stable over time, no reciprocal changes or Q waves.
  • Q: Underlying mechanism?A: Ito-mediated J-wave syndrome.

64.Paced rhythm (DDD)

  • ECG hallmark: Atrial and ventricular pacing spikes; RV pacing gives an LBBB-like QRS with left superior axis (apical lead).
  • Diagnosis: Dual-chamber paced rhythm
  • Clinical risk: Pacemaker malfunction.
  • Management: Device interrogation; chest X-ray for lead position; check thresholds and impedance.
Viva questions (5)
  • Q: QRS morphology?A: LBBB-like with RV pacing.
  • Q: Failure to capture?A: Pacing spike without a following depolarisation.
  • Q: Failure to pace?A: No spike when one is expected.
  • Q: Oversensing vs undersensing?A: Oversensing: the device detects noise and inhibits pacing (pauses). Undersensing: it misses intrinsic beats and paces inappropriately.
  • Q: Lead position?A: RV apex or septum; conduction system pacing is increasingly used.

65.Long QT type 1 (LQT1)

  • ECG hallmark: Broad-based T waves with long QTc.
  • Diagnosis: LQT1
  • Clinical risk: Sudden death during exercise, especially swimming.
  • Management: Non-selective beta-blocker (nadolol or propranolol); avoid competitive swimming.
Viva questions (5)
  • Q: Trigger?A: Exercise, particularly swimming.
  • Q: Gene?A: KCNQ1 (IKs).
  • Q: First-line?A: Beta-blocker — most effective in LQT1.
  • Q: ECG feature?A: Broad-based T wave.
  • Q: How does LQT2/LQT3 differ?A: LQT2: notched low-amplitude T, auditory triggers; LQT3: late-onset T, events at rest or sleep.

66.Sinus pause and SA exit block

  • ECG hallmark: Sinus pause: absent P–QRS for a period that is not a multiple of the P–P interval. SA exit block: the pause is an exact multiple of the P–P interval.
  • Diagnosis: Sinus pause / sinoatrial exit block
  • Clinical risk: Syncope; part of sick sinus syndrome.
  • Management: Pacemaker if symptomatic.
Viva questions (5)
  • Q: Significant pause length?A: ≥3 seconds while awake (or >2 s with symptoms).
  • Q: Rhythm?A: Sinus with intermittent failure.
  • Q: Symptoms?A: Syncope or dizziness.
  • Q: Causes?A: Sinus node fibrosis, drugs, vagal tone, ischaemia.
  • Q: When pacemaker?A: When pauses correlate with symptoms.

DIschaemia, conduction and drug ECGs

67.Hyperacute T waves

  • ECG feature: Broad-based, tall, symmetrical T-waves preceding significant ST-elevation.
  • Pathophysiology: Local potassium efflux from acutely ischaemic myocytes in the first minutes of coronary occlusion.
  • Clinical pearl: "Hyperacute" signifies the earliest phase of an evolving STEMI.
  • Differential: Hyperkalaemia gives narrow-based, peaked (tented) T waves; hyperacute T waves are broad-based and bulky relative to the QRS.
  • Management: Repeat ECGs every 15–30 minutes; treat as evolving STEMI and activate the cath lab for primary PCI when the picture is clear.

68.Left main / severe multivessel ischaemia (ST elevation in aVR)

  • ECG feature: ST depression ≥1 mm in eight or more leads with ST elevation in aVR and/or V1 (ESC 2023).
  • Pathophysiology: Diffuse subendocardial ischaemia from left main or severe three-vessel disease (or global supply–demand mismatch).
  • Clinical pearl: aVR elevation suggests left main or proximal multivessel disease, but the same pattern occurs with severe supply–demand ischaemia (anaemia, tachyarrhythmia, hypotension).
  • Clinical goal: Recognise a high-mortality pattern; if haemodynamically unstable, arrange immediate angiography.
  • Management: Urgent coronary angiography; revascularisation by PCI or CABG according to anatomy and Heart Team; mechanical support (IABP/Impella) if in shock.

69.Right ventricular infarction

  • ECG feature: ST elevation ≥1 mm in V4R (right-sided chest leads), usually with inferior STEMI.
  • Clinical pearl: Suspect in any inferior STEMI (II, III, aVF elevation).
  • Hemodynamics: The RV is preload-dependent; nitrates and diuretics can cause profound hypotension.
  • Clinical goal: Maintain RV preload with cautious IV fluids; avoid nitrates; treat bradycardia or AV block (pacing if needed).
  • Management: Primary PCI of the culprit (usually proximal RCA).

70.Spodick's sign

  • ECG feature: Downsloping of the TP segment, most easily seen in leads II and lateral precordials.
  • Pathophysiology: Atrial injury current and diffuse epicardial inflammation in acute pericarditis.
  • Clinical pearl: Seen in many patients with acute pericarditis but rare in STEMI; supportive, not diagnostic on its own.
  • Clinical goal: Helps differentiate pericarditis from other causes of ST elevation.
  • Management: Treat acute pericarditis with standard anti-inflammatory protocols.

71.LV aneurysm (persistent ST elevation)

  • ECG feature: Persistent ST elevation in anterior leads (V1-V4) months after an anterior MI.
  • Pathophysiology: Persistent ST elevation over a thin, dyskinetic transmural scar.
  • Clinical pearl: Q waves with persistent ST elevation and small T waves (T/QRS amplitude ratio < 0.36 in V1–V4) favour an old aneurysm over acute anterior STEMI.
  • Diagnostic tip: Compare with old ECGs; echo or CMR confirms the aneurysm and looks for LV thrombus.
  • Management: Anticoagulation if LV thrombus; GDMT for LV dysfunction; surgical aneurysmectomy or VT ablation for refractory heart failure or ventricular arrhythmias.

72.First-degree AV block

  • ECG feature: PR interval > 200ms; constant, 1:1 atrial-to-ventricular conduction.
  • Pathophysiology: Delay, usually at the AV node; often benign.
  • Clinical pearl: Can be seen in trained athletes or due to increased vagal tone.
  • Clinical goal: Rule out structural disease or electrolyte abnormalities.
  • Management: Usually observation; review AV-nodal blocking drugs; pacing only if PR is very long (>300 ms) with symptoms resembling pacemaker syndrome.

73.Mobitz type I (Wenckebach) AV block

  • ECG feature: Progressive PR prolongation until a beat is dropped (the "group beating" phenomenon).
  • Pathophysiology: Decremental conduction in the AV node, often from high vagal tone, drugs or inferior MI.
  • Clinical pearl: Rarely progresses to high-grade block; common in inferior MI or athlete’s heart.
  • Clinical goal: Monitor heart rate and hemodynamics; usually asymptomatic.
  • Management: Treat only if symptomatic or haemodynamically unstable (atropine); remove AV-nodal blocking drugs; pacing is rarely needed.

74.Tricyclic antidepressant overdose

  • ECG feature: Sinus tachycardia; QRS >100 ms; terminal R wave in aVR >3 mm; right axis of the terminal 40 ms.
  • Pathophysiology: Sodium channel blockade + anticholinergic effects.
  • Clinical pearl: QRS >100 ms predicts seizures and QRS >160 ms predicts ventricular arrhythmias.
  • Clinical goal: Give IV sodium bicarbonate when QRS exceeds 100 ms or with arrhythmia or hypotension.
  • Management: IV Sodium Bicarbonate; treat seizures with Benzodiazepines.

ENarrow and wide complex tachycardias

75.Atypical atrial flutter

  • ECG feature: Flutter waves that do not fit the typical pattern; morphology depends on the circuit (often after atrial surgery or ablation). Reverse typical (clockwise CTI) flutter has positive flutter waves in the inferior leads but is still CTI-dependent.
  • Pathophysiology: Often scars from prior atrial surgery or ablation (e.g., mitral valve surgery/AF ablation).
  • Clinical pearl: Usually not cured by CTI ablation alone; needs 3D electro-anatomical and entrainment mapping.
  • Clinical goal: Distinguish from typical flutter to guide procedural planning.
  • Management: Electrophysiological mapping and target-specific ablation.

76.Multifocal atrial tachycardia (MAT)

  • ECG feature: Rate >100 bpm; three or more distinct P-wave morphologies; varying PR intervals; isoelectric baseline between P waves.
  • Pathophysiology: Multiple competing atrial foci; classic association with severe COPD/lung disease.
  • Clinical pearl: Do not confuse with AF; the presence of P-waves (morphology changes) is key.
  • Clinical goal: Treat the underlying pulmonary exacerbation/hypoxia.
  • Management: Treat the underlying lung disease and hypoxia; correct potassium and magnesium; verapamil or a cardioselective beta-blocker if rate control is needed. Digoxin and cardioversion are ineffective.

77.Typical AVNRT (slow–fast)

  • ECG feature: Regular narrow-QRS tachycardia; retrograde P hidden in or just after the QRS (RP < 70 ms): pseudo-r′ in V1, pseudo-S in II, III, aVF.
  • Pathophysiology: Reentry within the AV node (dual pathways).
  • Clinical pearl: The most common form of PSVT.
  • Clinical goal: Terminate with vagal manoeuvres or adenosine.
  • Management: Acute: vagal manoeuvres, then adenosine. Long-term: slow-pathway ablation (first line, about 95–98% success); beta-blocker or calcium-channel blocker if ablation is declined.

78.Orthodromic AVRT

  • ECG feature: Regular narrow-QRS tachycardia; retrograde P wave in the ST segment (RP > 70 ms, RP < PR).
  • Pathophysiology: AV node conduction (antegrade) + Accessory Pathway (retrograde).
  • Clinical pearl: QRS alternans is more common in AVRT, but it is rate-related and not specific.
  • Clinical goal: Look for a delta wave on the sinus-rhythm ECG (absent with a concealed pathway).
  • Management: Vagal manoeuvres/Adenosine; ablation of the accessory pathway.

79.Focal atrial tachycardia

  • ECG feature: Narrow QRS; regular P-waves with abnormal axis/morphology preceding the QRS.
  • Pathophysiology: Single focus firing faster than the SA node.
  • Clinical pearl: "Warm-up" and "cool-down" phenomenon on ECG strip.
  • Clinical goal: Localize the focus based on the P-wave axis (e.g., Superior vs. Inferior).
  • Management: Beta-blockers/Non-DHP CCBs; if recurrent, focal ablation.

80.Junctional ectopic tachycardia (JET)

  • ECG feature: Regular narrow QRS; AV dissociation with P-waves firing slower than QRS complexes.
  • Pathophysiology: Enhanced automaticity in the AV junction; most common early after paediatric cardiac surgery (e.g., VSD or tetralogy repair).
  • Clinical pearl: Often hemodynamically compromised due to loss of AV synchrony.
  • Clinical goal: Maintain hemodynamics; identify post-op etiology.
  • Management: Reduce inotropes, correct electrolytes, cool to mild hypothermia (children), sedation, IV amiodarone; atrial pacing above the JET rate restores AV synchrony.

81.Polymorphic VT (ischaemic)

  • ECG feature: Irregular wide QRS; shifting QRS axis; Normal QT interval at baseline.
  • Pathophysiology: Triggered activity due to acute ischemia or electrolyte imbalance.
  • Clinical pearl: Distinguish from Torsades de Pointes (QT is normal here).
  • Clinical goal: Urgent search for coronary occlusion or electrolyte disturbance.
  • Management: Defibrillate if unstable; urgent revascularisation; correct potassium and magnesium; IV amiodarone and beta-blockers.

82.RVOT ventricular tachycardia

  • ECG feature: LBBB morphology with inferior axis (positive in II, III, aVF); precordial transition at V3 or later.
  • Pathophysiology: cAMP-mediated triggered activity or abnormal automaticity in the RV outflow tract.
  • Clinical pearl: Typically occurs in structurally normal hearts ("Idiopathic VT").
  • Clinical goal: Often exercise- or stress-provoked (catecholamine-sensitive); exclude ARVC and other structural disease with echo/CMR.
  • Management: Beta-blockers/Non-DHP CCBs; radiofrequency catheter ablation if symptomatic.

83.LVOT / aortic cusp ventricular tachycardia

  • ECG feature: Inferior axis with early precordial transition (R/S ≥1 by V2); LBBB-like from the aortic cusps, RBBB-like from the mitral annulus or aorto-mitral continuity.
  • Pathophysiology: Originates near the aortic/mitral valve annuli (LVOT).
  • Clinical pearl: Can present with either LBBB or RBBB depending on exact location (e.g., aortic cusp vs. mitral annulus).
  • Clinical goal: Identify if origin is aortic or mitral to guide ablation.
  • Management: Radiofrequency ablation; Beta-blockers as first-line.

84.Fascicular VT (Belhassen, verapamil-sensitive)

  • ECG feature: RBBB morphology with Left Axis Deviation (LAD); narrow-ish QRS (usually <140 ms).
  • Pathophysiology: Re-entry involving the left posterior fascicle (most common), giving RBBB with left axis.
  • Clinical pearl: Classic "Verapamil-sensitive" VT.
  • Clinical goal: Do not mistake for SVT with RBBB; avoid unnecessary shock if hemodynamically stable.
  • Management: Verapamil (Class IV antiarrhythmic); ablation for definitive cure.

85.Antidromic AVRT

  • ECG feature: Wide QRS tachycardia (fully pre-excited); looks identical to VT.
  • Pathophysiology: Accessory pathway used for antegrade conduction; AV node for retrograde.
  • Clinical pearl: Delta waves on the sinus-rhythm ECG support the diagnosis.
  • Clinical goal: Treat as VT if diagnosis is unclear; avoid AV nodal blockers if unsure.
  • Management: Procainamide (or ibutilide); synchronised cardioversion if unstable; then ablation of the accessory pathway. Avoid AV-nodal blockers if pre-excited AF cannot be excluded.

86.Pre-excited atrial fibrillation (WPW with AF)

  • ECG feature: Fast, Broad, Irregular (FBI) rhythm; R-R intervals vary significantly.
  • Pathophysiology: AF conducting through an accessory pathway with very short refractory period.
  • Clinical pearl: Highly lethal; can degenerate into Ventricular Fibrillation (VF).
  • Clinical goal: Avoid AV-nodal blockers (adenosine, beta-blockers, verapamil/diltiazem, digoxin) and IV amiodarone — they can accelerate conduction down the pathway (ESC 2019).
  • Management: Synchronised cardioversion if unstable; otherwise IV procainamide or ibutilide; then catheter ablation of the pathway.

87.Bix rule (hidden 2:1 P waves)

  • ECG feature: Regular tachycardia (often around 150 bpm) with a P wave sitting exactly midway between QRS complexes.
  • Pathophysiology: Bix rule: when an atrial wave sits halfway between two QRS complexes, suspect a second atrial wave hidden in the QRS — i.e., 2:1 atrial flutter or atrial tachycardia.
  • Clinical pearl: Look for subtle deformation of the QRS or ST segment that marks the hidden P wave.
  • Clinical goal: Avoid misdiagnosing sinus tachycardia or AVNRT.
  • Management: Vagal manoeuvres or adenosine slow AV conduction and unmask the flutter or atrial tachycardia; then rate control, anticoagulation decisions and ablation as appropriate.

FInherited and structural ECGs

88.Catecholaminergic polymorphic VT (CPVT)

  • ECG feature: Normal baseline ECG; exercise/emotional stress induces bidirectional VT (alternating QRS axis) or polymorphic VT.
  • Pathophysiology: Ryanodine receptor (RyR2) mutation leading to calcium handling defects.
  • Clinical pearl: Suspect in a young person with syncope during sports.
  • Clinical goal: Exercise testing is the key diagnostic test (reproduces ventricular ectopy and bidirectional or polymorphic VT); genetic testing (RYR2, CASQ2) and family screening.
  • Management: Non-selective beta-blocker (nadolol preferred); add flecainide; left cardiac sympathetic denervation if breakthrough; ICD for survivors of cardiac arrest (with beta-blocker). Avoid competitive sport.

89.Short QT syndrome

  • ECG feature: QTc ≤320 ms, or ≤360 ms with a pathogenic variant, family history or survived arrest (ESC 2022); tall, peaked T waves.
  • Pathophysiology: Gain-of-function mutations in potassium channels (KCNH2, KCNQ1, KCNJ2).
  • Clinical pearl: Predisposes to both atrial and ventricular arrhythmias (AF and VF).
  • Clinical goal: Diagnose based on short QT and clinical history of syncope/SCD.
  • Management: ICD for survivors of cardiac arrest or sustained VT; quinidine to prolong the QT or if ICD is declined.

90.Alternating bundle branch block

  • ECG feature: RBBB and LBBB alternating on consecutive beats or daily.
  • Pathophysiology: Disease of both bundle branches; conduction may fail completely at any time.
  • Clinical pearl: Suggests advanced trifascicular conduction system degeneration.
  • Clinical goal: High risk of complete heart block and syncope.
  • Management: Permanent pacemaker (ESC 2021 Class I, even without symptoms).

91.Macruz index

  • ECG feature: Ratio of P-wave duration to PR-segment duration in lead II (normal about 1.0–1.6).
  • Pathophysiology: Ratio >1.6 suggests left atrial enlargement; <1.0 suggests right atrial enlargement.
  • Clinical pearl: Used in older literature to distinguish LAE from RAE.
  • Clinical goal: Correlate with current Echo findings (not the primary tool today).
  • Management: Treat the primary valvular or myocardial pathology.

Distinction viva tip — inherited syndromes: answer in three steps. “This ECG shows [name]. It indicates [a channelopathy or structural] risk. My management is [ICD or medication], and I will arrange genetic testing and screening of first-degree relatives.” Mentioning family screening shows you understand the wider implications.

GAdvanced EP tracings

92.Selective His bundle pacing

  • EP feature: Pacing stimulus-to-QRS interval equals the native HV interval, with an isoelectric gap after the spike.
  • Significance: Capture is confined strictly to the His-Purkinje system.
  • QRS morphology: Identical to native QRS.
  • Clinical goal: Physiological pacing; avoids RV pacing dyssynchrony.
  • Management: Check capture thresholds closely (often higher than RV pacing); used to avoid RV-pacing dyssynchrony and can correct some LBBB; left bundle branch area pacing is an alternative.

93.Non-selective His bundle pacing

  • EP feature: Spike followed by a small "delta-wave" slurring; captures both His and local RV myocardium.
  • Significance: The pacing energy is sufficient to capture both the His and adjacent septal muscle.
  • QRS morphology: Widened (fused appearance).
  • Clinical goal: Ensure adequate septal recruitment if His-only capture is lost.
  • Management: Titrate output to find the lowest threshold for His-bundle capture.

94.Para-Hisian pacing

  • EP feature: Pacing RV septum near His at high vs. low output.
  • Significance: Differentiates VA conduction (AV node vs. accessory pathway).
  • Clinical goal: High output captures the His bundle and septum; low output captures only the septal myocardium. If the stimulus-to-atrium interval stays the same when His capture is lost, retrograde conduction is via a septal accessory pathway; if it lengthens, conduction is via the AV node.
  • Management: Diagnostic manoeuvre for SVT mechanism mapping.

95.Entrainment mapping (PPI − TCL)

  • EP feature: Post-pacing interval (PPI) minus tachycardia cycle length (TCL) after entrainment.
  • Significance: PPI − TCL ≤ 30 ms means the pacing site is within the re-entry circuit; with concealed fusion it marks the critical isthmus.
  • Clinical goal: Target this area for ablation.
  • Management: Ablation at the site of PPI-TCL < 30ms.

96.Atypical AVNRT (fast–slow)

  • EP feature: Long RP tachycardia; retrograde P-waves (negative in II, III, aVF) occur before the next QRS.
  • Significance: Reentry using the Fast pathway for antegrade and Slow for retrograde conduction.
  • Clinical pearl: Distinguish from Focal Atrial Tachycardia.
  • Management: Ablation of the Slow pathway.

97.Coumel's law

  • EP feature: During orthodromic AVRT, the VA interval and cycle length lengthen (by about 35 ms or more) when bundle branch block develops on the same side as the accessory pathway.
  • Significance: Proves an accessory pathway participates in the tachycardia and lateralises it to the side of the bundle branch block.
  • Clinical goal: Localize the accessory pathway without further mapping.
  • Management: Utilize as a navigational guide for catheter positioning.

98.Concealed accessory pathway

  • EP feature: Normal baseline ECG (no delta wave) but sustains orthodromic AVRT.
  • Significance: Pathway conducts only retrogradely.
  • Clinical pearl: Cannot be seen on surface ECG; only identified during EP study.
  • Management: Ablation of the pathway at the site of earliest retrograde A.

99.His-refractory PVC (resetting the SVT)

  • EP feature: A PVC delivered when the His bundle is refractory advances, delays or terminates the tachycardia.
  • Significance: The ventricle can reach the atrium without the AV node, so an accessory pathway is present (and participates if the SVT is reset or terminated without atrial activation).
  • Clinical goal: Differentiate orthodromic AVRT from AVNRT and atrial tachycardia.
  • Management: Targeted ablation of the accessory pathway.

100.Dual AV nodal non-reentrant tachycardia (DAVNNT)

  • EP feature: “1 for 2” response: one sinus P wave conducts down both fast and slow pathways, giving two QRS complexes.
  • Significance: Simultaneous conduction through two pathways causes two QRS complexes.
  • Clinical goal: Recognize as a non-reentrant (automaticity/conduction) phenomenon.
  • Management: Can mimic AF or cause tachycardiomyopathy; slow-pathway ablation is curative when symptomatic.

101.Concealed His-bundle extrasystole

  • EP feature: An extrasystole from the His bundle that conducts neither forward nor backward but leaves the AV node refractory.
  • Significance: Can mimic Mobitz type I or II block (pseudo-AV block) on the surface ECG.
  • Clinical pearl: The "hidden" impulse renders the AV node unable to conduct the next sinus beat.
  • Management: Observation; distinguish from intrinsic conduction disease.

102.Entrainment of typical atrial flutter

  • EP feature: Pacing from the cavotricuspid isthmus during flutter gives concealed entrainment with PPI − TCL ≤ 20–30 ms.
  • Significance: Confirms the CTI as the critical, required component of the circuit.
  • Clinical goal: Confirm a CTI-dependent circuit before ablation.
  • Management: CTI ablation (line of block).

103.Eccentric coronary sinus activation

  • EP feature: Earliest retrograde A at distal CS (1,2) instead of His.
  • Significance: Confirms a left-sided accessory pathway.
  • Clinical pearl: "Eccentric" activation is the hallmark of left-sided pathology.
  • Management: Ablation of the left-sided pathway via transseptal or retrograde aortic access.

104.Concentric coronary sinus activation

  • EP feature: Retrograde atrial activation is earliest at the proximal coronary sinus (near the ostium) and spreads to the distal coronary sinus.
  • Significance: Normal (AV nodal) retrograde activation — seen with AVNRT or a septal accessory pathway.
  • Clinical goal: Differentiate from eccentric (left-sided) pathways.
  • Management: Ablation at the triangle of Koch (AVNRT) or septal region.

105.AH jump and echo beat

  • EP feature: An AH interval increase of 50 ms or more for a 10 ms shortening of the atrial extrastimulus, often followed by an echo beat.
  • Significance: Demonstrates dual AV nodal physiology (Slow/Fast pathway).
  • Clinical pearl: The jump marks block in the fast pathway with conduction down the slow pathway.
  • Management: Slow pathway ablation to cure AVNRT.

Distinction viva tip — complex EP tracings: first define the A–V relationship, then the retrograde activation sequence, and finally use programmed stimulation (entrainment, PPI, resetting) to prove the circuit. Be ready to explain concentric (AV node, AVNRT or septal pathway) versus eccentric (left-sided accessory pathway) coronary sinus activation.

HPacemaker and device ECGs

106.Pacemaker failure to capture

  • ECG feature: Pacing spikes occur on time, but no QRS/P-wave follows; the myocardium remains electrically silent.
  • Pathophysiology: Rise in threshold (exit block, ischaemia, hyperkalaemia, antiarrhythmic drugs), lead dislodgement or fracture, or low output programming.
  • Clinical pearl: "Capture" is the myocardial response; the spike is just the energy delivery.
  • Clinical goal: Rule out emergency (e.g., ischemia or metabolic disturbance).
  • Management: Increase output; check electrolytes and drugs; chest X-ray and device check for lead position and impedance; temporary pacing if pacing-dependent.

107.Pacemaker undersensing

  • ECG feature: Pacing spikes appear despite intrinsic P waves or QRS complexes — they can fall on the T wave.
  • Pathophysiology: The sensing threshold (mV value) is set too high for the intrinsic signal, or the signal is small (lead dislodgement, scar, new bundle branch block).
  • Clinical pearl: Risk of R-on-T phenomenon (leading to VF).
  • Clinical goal: Make the channel more sensitive (programme a lower mV value).
  • Management: Reprogramme sensitivity; check lead position and signal amplitude.

108.Pacemaker oversensing

  • ECG feature: Unexpected pauses; the device "sees" noise (e.g., pectoralis twitch, T-waves) and inhibits its output.
  • Pathophysiology: The channel is too sensitive (mV value too low), so it counts noise, myopotentials, T waves or far-field signals as beats.
  • Clinical pearl: Can cause life-threatening bradycardia or asystole.
  • Clinical goal: Eliminate the noise source or make the channel less sensitive (higher mV value).
  • Management: Apply a magnet in a pacemaker-dependent patient; reprogramme sensitivity or polarity; look for lead fracture or insulation breach.

109.Pacemaker-mediated tachycardia (PMT)

  • ECG feature: Regular paced tachycardia at or below the upper tracking rate, with retrograde P waves after each paced QRS (“endless loop”).
  • Pathophysiology: Retrograde atrial conduction (V-A) triggers the pacemaker to track the P-wave, firing the ventricle again.
  • Clinical pearl: A magnet stops it acutely (asynchronous pacing); prevention is a longer PVARP or PMT-termination algorithms.
  • Clinical goal: Prevent endless loops.
  • Management: Extend PVARP; magnet application to stop the loop.

110.Normal VVI pacing

  • ECG feature: Ventricular spikes followed by wide, paced QRS; complete AV dissociation (intrinsic atrial activity continues independently).
  • Pathophysiology: Ventricular-only pacing; device ignores the atrium.
  • Clinical pearl: Appropriate for patients with permanent AF.
  • Clinical goal: Ensure pacing rate is appropriate for the clinical status.
  • Management: Standard follow-up.

111.CRT biventricular pacing

  • ECG feature: Synchronized pacing of both ventricles; narrower QRS than standard RV pacing; dominant R in V1.
  • Pathophysiology: Biventricular pacing reduces mechanical dyssynchrony in heart failure.
  • Clinical pearl: A narrower QRS than RV pacing and a dominant R in V1 (with a Q in I) indicate effective LV capture.
  • Clinical goal: Optimize RV-LV offset timing.
  • Management: Optimization via device programming/echo-guided pacing intervals.

112.Magnet application

  • ECG feature: Pacemaker: asynchronous pacing (VOO or DOO) at the magnet rate, ignoring the intrinsic rhythm.
  • Pathophysiology: Default "safety mode" overrides sensing to prevent inhibition by EMI (e.g., during surgery).
  • Clinical pearl: The magnet rate is manufacturer-specific and falls as the battery depletes (elective replacement indicator). On an ICD, a magnet suspends tachycardia therapies but does not change the pacing mode.
  • Clinical goal: Check battery status, prevent inhibition by electrocautery, or stop pacemaker-mediated tachycardia.
  • Management: Remove magnet to restore normal sensing and physiologic pacing.

113.Crosstalk (ventricular inhibition by atrial output)

  • Mechanism: The ventricular channel senses the atrial pacing output just after the post-atrial ventricular blanking period.
  • Consequence: Inappropriate inhibition of ventricular pacing — dangerous pauses in a pacing-dependent patient.
  • ECG feature: Atrial spike present, but ventricular output is inhibited when it should have fired.
  • Clinical goal: Differentiate from failure to capture or undersensing; ventricular safety pacing is the built-in protection.
  • Management: Lengthen ventricular blanking, lower atrial output, make the ventricular channel less sensitive or use bipolar sensing.

114.Ventricular safety pacing

  • Mechanism: Any ventricular sensing in the early window after an atrial paced beat (about 100–110 ms) could be crosstalk.
  • Consequence: The device delivers a ventricular pace at a short AV delay (about 100–110 ms) instead of inhibiting, preventing asystole.
  • ECG feature: Ventricular spike about 100–110 ms after the atrial spike, often during a PVC or junctional beat.
  • Management: Normal safety behaviour; frequent episodes suggest crosstalk or atrial lead problems — check programming and leads.

115.Upper rate behaviour: pacemaker Wenckebach

  • Mechanism: Atrial rate above the maximum tracking rate but below the 2:1 block rate.
  • Consequence: The paced AV delay lengthens progressively until a P wave falls in the PVARP and is not tracked.
  • ECG feature: Progressively lengthening P-to-spike (AV) interval until a ventricular beat is dropped.
  • Management: Increase MTR or program Rate-Adaptive AV Delay.

116.Upper rate behaviour: 2:1 block

  • Mechanism: Atrial rate exceeds the rate set by the total atrial refractory period (TARP = AV delay + PVARP).
  • Consequence: Every second P-wave falls in the refractory period; the device ignores it.
  • ECG feature: P-P interval is constant, but every other P-wave is not followed by a ventricular pace.
  • Management: Shorten the AV delay (rate-adaptive) or PVARP to shorten TARP, if appropriate.

117.Automatic mode switch

  • Mechanism: Detection of rapid atrial rate (e.g., AF) exceeding the trigger threshold.
  • Consequence: Device stops tracking the atrium (DDD → DDI/VVI) to prevent tracking of AF into the ventricles.
  • Clinical goal: Prevents hemodynamically unstable rapid ventricular response.
  • Management: Review the "Mode Switch" duration criteria and atrial sensitivity.

118.Pseudo-pseudofusion

  • Mechanism: In a dual-chamber device, the atrial spike falls within the QRS of an intrinsic ventricular beat.
  • Consequence: The spike has no effect on the ventricle and can look like a sensing failure.
  • Clinical pearl: Normal timing behaviour — the ventricular lead had not yet sensed the QRS.
  • Management: No action required; it is an artifact of timing.

119.Rate hysteresis

  • Mechanism: The device allows the intrinsic rate to fall to a lower hysteresis rate before it starts pacing at the programmed base rate.
  • Consequence: Preserves the intrinsic rhythm and reduces unnecessary pacing.
  • Clinical goal: Preserve intrinsic rhythm; reduce unnecessary RV pacing.
  • Management: Program based on clinical need for heart rate support.

120.Sleep (rest) rate function

  • Mechanism: Automates rate reduction during expected sleep hours or via sensor-driven activity tracking.
  • Consequence: Prevents "over-pacing" and improves patient comfort/battery longevity.
  • Management: Ensure the sensor is functioning; adjust based on patient's lifestyle.

121.Runaway pacemaker

  • Mechanism: Rare generator failure (usually battery depletion or circuit damage) producing rapid pacing; modern devices have runaway protection.
  • Consequence: Potential for catastrophic ventricular tachycardia/fibrillation.
  • Management: Emergency: a magnet may not help; urgent generator replacement or disconnecting/cutting the lead with temporary pacing backup.

122.ICD anti-tachycardia pacing: burst

  • Mechanism: Fixed-rate, rapid pacing sequence faster than the detected VT rate.
  • Consequence: Painless termination of VT by "capturing" the circuit and rendering it refractory.
  • Clinical goal: First-line therapy for monomorphic VT, including fast VT (188–250 bpm, PainFREE Rx II).
  • Management: Program as first-line therapy for stable VT.

123.ICD anti-tachycardia pacing: ramp

  • Mechanism: Pacing sequence where the cycle length shortens (rate speeds up) with each pulse.
  • Consequence: Can terminate VT that fails burst pacing.
  • Clinical goal: Burst is usually programmed first; ramp is a second-line option with a slightly higher risk of accelerating VT.
  • Management: Program as second/third line if burst ATP fails.

124.T-wave oversensing (ICD)

  • Mechanism: ICD lead senses the T-wave as a second QRS, doubling the count.
  • Consequence: Falsely high heart rate detection leads to an inappropriate shock.
  • Clinical goal: Reprogramme sensing (decay, threshold or filters) or change the sensing vector; correct hyperkalaemia if present.
  • Management: Device reprogramming; adjust sensitivity.

125.Far-field R-wave oversensing

  • Mechanism: The atrial lead senses ventricular depolarisation (far-field R wave).
  • Consequence: The device counts ventricular activity as atrial events — false high atrial rates, inappropriate mode switching or PVARP-related problems.
  • Clinical goal: Lengthen post-ventricular atrial blanking, make the atrial channel less sensitive or use bipolar sensing.
  • Management: Adjust sensitivity or physical lead repositioning.

126.Loss of biventricular capture

  • Mechanism: LV lead dislodgement or threshold rise, output reduced to avoid phrenic nerve stimulation, or loss of BiV pacing from AF or frequent PVCs.
  • Consequence: Loss of CRT; QRS widens to an RV-paced (LBBB-like) pattern; heart failure symptoms may return.
  • Clinical goal: Urgent device interrogation to confirm LV lead parameters.
  • Management: Reprogram LV output; if dislodged, surgical/percutaneous lead repositioning.

127.Lead fracture vs insulation breach

  • Fracture: High impedance (typically above 2000 Ω, or an abrupt rise): open circuit, noise or oversensing, loss of capture.
  • Insulation breach: Low impedance (typically below 200 Ω, or an abrupt fall): current leak, rapid battery drain, oversensing and loss of capture.
  • Clinical goal: Differentiate by impedance trends, noise on the electrogram and the chest X-ray.
  • Management: Both usually need lead replacement (or a new lead); check the generator for battery depletion after an insulation breach.

Distinction viva tip — device strips: ask three questions — is the spike present and on time (timing/output)? Is there capture (threshold)? Is sensing appropriate (over- or undersensing)? Then assess haemodynamics, apply a magnet if a pacemaker problem is dangerous (remembering a magnet on an ICD only suspends tachy-therapies), and interrogate the device for impedance, thresholds and stored electrograms.

Classes and cut-offs follow the ESC 2020–2024 and ACC/AHA guidelines current in October 2026; always apply your own institution's protocols.

meritmedscript.comDr. Sidhartha Mullapudi